ArticleThe Journal of innovations in cardiac rhythm management2025
Cardiac Contractility Modulation Therapy and Device Algorithm-related Challenges.
Article in The Journal of innovations in cardiac rhythm management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inappropriate shocks from subcutaneous defibrillator in the presence of a cardiac contractility modulation device.HeartRhythm case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a complex and potentially life-threatening medical condition posing significant risks to individuals. It is associated with substantial health care expenditures, considerable morbidity and mortality, and a decline in functional capacity and quality of life. Cardiac contractility modulation (CCM) has emerged as a promising device-based treatment for patients with HF with reduced ejection fraction (HFrEF). Studies have shown that CCM treatment in HFrEF patients can improve exercise tolerance and quality of life and reduce HF hospitalizations. As CCM therapy becomes a more prevalent treatment for HFrEF, the natural learning curve inherent in the use of new technologies necessitates broader provider training and careful patient follow-up. To that end, this article highlights the importance of developing a fundamental troubleshooting algorithm to help optimize the management of patients who have an implanted CCM device.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.